Long-term Protection Associated With COVID-19 Vaccination and Prior Infection

doi:10.1001/jama.2022.14660

Comment

. 2022 Oct 11;328(14):1402-1404.

doi: 10.1001/jama.2022.14660.

Long-term Protection Associated With COVID-19 Vaccination and Prior Infection

Mark W Tenforde¹, Ruth Link-Gelles¹, Manish M Patel¹

Affiliations

PMID: 36156638
PMCID: PMC11331586
DOI: 10.1001/jama.2022.14660

Comment

Long-term Protection Associated With COVID-19 Vaccination and Prior Infection

Mark W Tenforde et al. JAMA. 2022.

. 2022 Oct 11;328(14):1402-1404.

doi: 10.1001/jama.2022.14660.

Authors

Mark W Tenforde¹, Ruth Link-Gelles¹, Manish M Patel¹

Affiliation

¹ CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

PMID: 36156638
PMCID: PMC11331586
DOI: 10.1001/jama.2022.14660

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Comment in

Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.
Lin DY, Gu Y, Xu Y, Wheeler B, Young H, Sunny SK, Moore Z, Zeng D. Lin DY, et al. JAMA. 2022 Oct 11;328(14):1415-1426. doi: 10.1001/jama.2022.17876. JAMA. 2022. PMID: 36155617 Free PMC article.

Comment on

Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.
Lin DY, Gu Y, Xu Y, Wheeler B, Young H, Sunny SK, Moore Z, Zeng D. Lin DY, et al. JAMA. 2022 Oct 11;328(14):1415-1426. doi: 10.1001/jama.2022.17876. JAMA. 2022. PMID: 36155617 Free PMC article.

Cited by

Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand, 2023.
Mahasing C, Suphanchaimat R, Teekasap P, Nittayasoot N, Wongsanuphat S, Thammawijaya P. Mahasing C, et al. PLoS One. 2024 Sep 17;19(9):e0310427. doi: 10.1371/journal.pone.0310427. eCollection 2024. PLoS One. 2024. PMID: 39288199 Free PMC article.
Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022.
Kojima N, Adams K, Self WH, Gaglani M, McNeal T, Ghamande S, Steingrub JS, Shapiro NI, Duggal A, Busse LW, Prekker ME, Peltan ID, Brown SM, Hager DN, Ali H, Gong MN, Mohamed A, Exline MC, Khan A, Wilson JG, Qadir N, Chang SY, Ginde AA, Withers CA, Mohr NM, Mallow C, Martin ET, Lauring AS, Johnson NJ, Casey JD, Stubblefield WB, Gibbs KW, Kwon JH, Baughman A, Chappell JD, Hart KW, Jones ID, Rhoads JP, Swan SA, Womack KN, Zhu Y, Surie D, McMorrow ML, Patel MM, Tenforde MW; Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. Kojima N, et al. Clin Infect Dis. 2023 Aug 22;77(4):547-557. doi: 10.1093/cid/ciad276. Clin Infect Dis. 2023. PMID: 37255285 Free PMC article.
Community focus groups about a COVID-19 individual risk assessment tool: access, understanding and usefulness.
Keval A, Titi M, Saleh HO, Young S, Gomez JD, Atanasov V, Black B, Meurer J. Keval A, et al. BMC Public Health. 2023 Sep 11;23(1):1761. doi: 10.1186/s12889-023-16696-3. BMC Public Health. 2023. PMID: 37697247 Free PMC article.
Protection against Severe Illness versus Immunity-Redefining Vaccine Effectiveness in the Aftermath of COVID-19.
Roche R, Odeh NH, Andar AU, Tulapurkar ME, Roche JA. Roche R, et al. Microorganisms. 2023 Jul 31;11(8):1963. doi: 10.3390/microorganisms11081963. Microorganisms. 2023. PMID: 37630523 Free PMC article. Review.
Vaccination status and disease severity of COVID-19 in different phases of the pandemic.
Yang X, Shi F, Zhang J, Gao H, Chen S, Olatosi B, Weissman S, Li X. Yang X, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2353491. doi: 10.1080/21645515.2024.2353491. Epub 2024 Jun 4. Hum Vaccin Immunother. 2024. PMID: 38832632 Free PMC article.

See all "Cited by" articles

References

1. Steele MK, Couture A, Reed C, et al. Estimated number of COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in the US, December 2020 to September 2021. JAMA Netw Open. 2022;5(7):e2220385. doi:10.1001/jamanetworkopen.2022.20385 - DOI - PMC - PubMed
1. COVID data tracker: vaccination distribution and coverage. Centers for Disease Control and Prevention. Accessed September 20, 2022. https://covid.cdc.gov/covid-data-tracker/#vaccinedelivery-coverage
1. Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies: United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(17):606–608. doi:10.15585/mmwr.mm7117e3 - DOI - PMC - PubMed
1. Jones JM, Opsomer JD, Stone M, et al. Updated US infection- and vaccine-induced SARS-CoV-2 seroprevalence estimates based on blood donations, July 2020-December 2021. JAMA. 2022; 328(3):298–301. doi:10.1001/jama.2022.9745 - DOI - PMC - PubMed
1. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021;326(19):19301939.doi:10.1001/jama.2021.19623 - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

CC999999/ImCDC/Intramural CDC HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Steele MK, Couture A, Reed C, et al. Estimated number of COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in the US, December 2020 to September 2021. JAMA Netw Open. 2022;5(7):e2220385. doi:10.1001/jamanetworkopen.2022.20385 - DOI - PMC - PubMed

[2] Steele MK, Couture A, Reed C, et al. Estimated number of COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in the US, December 2020 to September 2021. JAMA Netw Open. 2022;5(7):e2220385. doi:10.1001/jamanetworkopen.2022.20385 - DOI - PMC - PubMed

[3] COVID data tracker: vaccination distribution and coverage. Centers for Disease Control and Prevention. Accessed September 20, 2022. https://covid.cdc.gov/covid-data-tracker/#vaccinedelivery-coverage

[4] COVID data tracker: vaccination distribution and coverage. Centers for Disease Control and Prevention. Accessed September 20, 2022. https://covid.cdc.gov/covid-data-tracker/#vaccinedelivery-coverage

[5] Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies: United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(17):606–608. doi:10.15585/mmwr.mm7117e3 - DOI - PMC - PubMed

[6] Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies: United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(17):606–608. doi:10.15585/mmwr.mm7117e3 - DOI - PMC - PubMed

[7] Jones JM, Opsomer JD, Stone M, et al. Updated US infection- and vaccine-induced SARS-CoV-2 seroprevalence estimates based on blood donations, July 2020-December 2021. JAMA. 2022; 328(3):298–301. doi:10.1001/jama.2022.9745 - DOI - PMC - PubMed

[8] Jones JM, Opsomer JD, Stone M, et al. Updated US infection- and vaccine-induced SARS-CoV-2 seroprevalence estimates based on blood donations, July 2020-December 2021. JAMA. 2022; 328(3):298–301. doi:10.1001/jama.2022.9745 - DOI - PMC - PubMed

[9] Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021;326(19):19301939.doi:10.1001/jama.2021.19623 - DOI - PMC - PubMed

[10] Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021;326(19):19301939.doi:10.1001/jama.2021.19623 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Long-term Protection Associated With COVID-19 Vaccination and Prior Infection

Affiliation

Long-term Protection Associated With COVID-19 Vaccination and Prior Infection

Authors

Affiliation

Conflict of interest statement

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical